

Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Use of Immunotherapy for Endometrial Cancer — Microlearning Activity 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following factors is associated with a poor prognosis for patients with endometrial cancer (EC)?**
 - Endometrioid histology
 - Estrogen receptor negativity
 - Wild-type TP53 gene status
- 2. Which of the following HER2 molecular testing approaches is favored by the faculty for patients with metastatic EC?**
 - Test at initial diagnosis only
 - Test at disease recurrence only
 - Test at initial diagnosis, and repeat testing at recurrence if original results for the primary tumor are negative
 - HER2 testing is not recommended
- 3. An ongoing Phase III trial is evaluating the addition of bevacizumab to pembrolizumab and chemotherapy for which patients with EC?**
 - Patients with mismatch repair (MMR)-deficient, TP53 wild-type EC
 - Patients with MMR-deficient, TP53-mutant EC
 - Patients with MMR-proficient, TP53 wild-type EC
 - Patients with MMR-proficient, TP53-mutant EC
- 4. In general, which of the following statements best describes long-term outcomes with checkpoint inhibitor therapy for patients with MMR-proficient EC compared to patients with MMR-deficient EC?**
 - Long-term survival rates are equivalent
 - The long-term survival rate is lower with MMR-proficient EC than with MMR-deficient EC
 - The long-term survival rate is higher with MMR-proficient EC than with MMR-deficient EC.